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Background: Previous studies have predominantly evaluated the effectiveness of inpatient treatment for anorexia
nervosa at the group level. The aim of this study was to evaluate treatment outcomes at an individual level based
on the clinical significance of improvement. Patients’ treatment outcomes were classified into four groups:
deteriorated, unchanged, reliably improved and clinically significantly improved. Furthermore, the study set out to
explore predictors of clinically significant changes in eating disorder psychopathology.
Methods: A total of 435 inpatients were assessed at admission and at discharge on the following measures:
body-mass-index, eating disorder symptoms, general psychopathology, depression and motivation for change.
Results: 20.0-32.0% of patients showed reliable changes and 34.1-55.3% showed clinically significant changes in the
various outcome measures. Between 23.0% and 34.5% remained unchanged and between 1.7% and 3.0%
deteriorated. Motivation for change and depressive symptoms were identified as positive predictors of clinically
significant changes in eating disorder psychopathology, whereas body dissatisfaction, impulse regulation, social
insecurity and education were negative predictors.
Conclusions: Despite high rates of reliable and clinically significant changes following intensive inpatient
treatment, about one third of anorexia nervosa patients showed no significant response to treatment. Future
studies should focus on the identification of non-responders as well as on the development of treatment strategies
for these patients.
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Anorexia nervosa is characterized by a pronounced self-
induced weight loss or insufficient weight gain during
the period of growth and is associated with an irrational
fear of gaining weight as well as a conspicuous distortion
of body image. This disorder is relatively common
among young women. While the overall incidence rate
has remained stable over the past decades, there has
been an increased incidence in 15-19 year old girls, a
group at elevated risk [1]. The disorder is often charac-
terized by a chronic course and elevated mortality rates
[2,3] and thus is one of the diseases with the worst* Correspondence: sandra.schlegl@med.uni-muenchen.de
1Department of Psychiatry and Psychotherapy, University Hospital of Munich
(LMU), Munich, Germany
Full list of author information is available at the end of the article
© 2014 Schlegl et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.prognosis in psychiatry and psychosomatic medicine. Re-
cent state of the art studies suggest that treatment of an-
orexia nervosa in various settings (outpatient, inpatient,
day clinic) is effective [4-6]. In a large randomised con-
trolled trial investigating the efficacy of outpatient treat-
ment of anorexia nervosa significant weight gain as well
as reduction in general and eating disorder-specific psy-
chopathology was found [4]. For severe cases of anorexia
nervosa with high medical and/or psychosocial risk and
a lack of response to less intensive treatments, existing
practice guidelines advise inpatient treatment [7-9].
So far, statistical group comparisons have predomi-
nantly served to evaluate the effectiveness of inpatient
treatment for anorexia nervosa [10-13]. This approach
guarantees that the differences found are not based on
chance. Yet, it does not provide any information aboutLtd. This is an Open Access article distributed under the terms of the Creative
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addition, statistical significance does not enable conclu-
sions to be drawn about whether or not a change in
symptoms is clinically relevant [14]. Effect sizes (ES) are
better suited to evaluate therapeutic effects because they
provide information about the size of a change and are
independent of sample size. However, this measure is
also relatively independent of the clinical relevance of re-
sults [14]. Authors such as Long et al. [15], Rø et al.
[16], Tagay et al. [17], Zeeck et al. [18] and Goddard
et al. [19] reported small to high effect sizes of inpatient
treatment for anorexia nervosa depending on the out-
come measure.
To overcome the shortcomings of measuring treat-
ment outcome in terms of statistical significance or ef-
fect sizes, Jacobson and colleagues [14,20] developed a
concept that considers the clinical relevance of treat-
ment change on an individual basis.
To our knowledge, there is only one study that reports
clinically significant changes in inpatients with eating
disorders based on the criteria of Jacobson and Truax
[14]. Calugi and colleagues [21] found that after treat-
ment 36.4% of patients with longstanding eating disorder
(≥ 10 years) showed clinically significant changes in the
Global score of the Eating Disorder Examination (EDE
[22]) compared to 44.0% of those with shorter disease
duration. The rest of the patients remained unchanged,
no patient deteriorated.
Building on this previous literature, the aim of the
current study was to evaluate the outcome of inpatient
treatment for anorexia nervosa on an individual basis
using the criteria of clinical significance. We used a rela-
tivly wide range of outcome measures (body-mass-index
(BMI), eating disorder symptoms, general psychopath-
ology and depression). Furthermore, we intended to ex-




We investigated a sample of female inpatients who were
hospitalised at the Schoen Klinik Roseneck in Prien,
Germany between January 2009 and January 2014. Inclu-
sion criteria were a diagnosis of anorexia nervosa ac-
cording to ICD-10 (F50.00, F50.01) including intense
fear of gaining weight, a distorted body image and a
BMI less than or equal to 17.5. Patients were diagnosed
by experienced clinicians from the highly specialized eat-
ing disorder unit (all with a minimum master’s degree in
medicine or psychology) during a standard intake inter-
view. Furthermore, a minimum age of 18 years was
mandatory. Exclusion criteria were drug/alcohol/medica-
tion abuse, acute suicidal tendencies, psychotic symp-
toms or a severe life-threatening somatic disorder.Patients were ‘regularly’ discharged if they achieved
the target weight (BMI > 18 in accordance with eating
disorder guidelines [9]). Patients who did not achieve
the target weight (mostly those with a very low BMI at
admission) were ‘regularly’ discharged if follow-up treat-
ment was assured (e.g. a re-admission was planned).
Patients were ‘prematurely’ discharged if they had insuffi-
cient therapy motivation or for disciplinary reasons.
All participants gave written and signed informed con-
sent. The study was approved by the responsible Medical
Ethics Committee of the University of Munich.
Inpatient treatment program
All patients received a multimodal inpatient treatment
program based on cognitive-behavioural therapy with
group and individual psychotherapy. The manualised
eating disorder-specific group therapy consisted of nine
therapy sessions, each lasting 100 minutes. The main el-
ements were psycho-education, behavioural and func-
tional analysis, acceptance of one’s own body, dealing
with emotions and needs, and relapse prevention. The
general group psychotherapy took place up to three
times a week and each session lasted 90 to 100 minutes.
Patients received individual therapy once or twice a
week for one hour. Additional therapy elements included
social skills training, art therapy, attending classes in the
teaching kitchen and exercise therapy. Patients were re-
quired to gain 700 g of body weight per week. Co-
therapists weighed the patients twice a week in the
morning and weight gain was visualised on charts. If pa-
tients with anorexia nervosa failed to gain weight, fur-
ther steps were taken: increase of food intake and
monitoring during meal times, administration of high
caloric fluids or feeding through a nasal tube.
Measures
A standard set of self-rating questionnaires were used to
assess eating disorder symptomatology, general psycho-
pathology and depression at admission and discharge.
The Eating Disorder Inventory-2 (EDI-2) [23,24]
was used for the multidimensional assessment of the
specific psychopathology of patients with eating disor-
ders. It consists of 11 scales with 91 items that can be
answered on a six-point scale from 1 (never) to 6 (al-
ways). Cronbach’s Alpha for the EDI-2 Global score for
this sample was .96 at admission. Cronbach’s Alphas for
the subscales are given in online supplemental materials
(see Additional file 1).
The Brief Symptom Inventory (BSI) [25,26] assesses
current general psychological distress of patients through-
out the last week on the basis of 53 items belonging
to nine subscales. Answers are given on a five-point
scale, ranging from 0 (not at all) to 4 (extremely).
Three global parameters can be calculated. In the present
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Alpha for the GSI for this sample was .96.
The Beck Depression Inventory-2 (BDI-2) [27,28] is
a self-rating instrument to assess the severity of depres-
sive symptoms. Patients can rate each item on a four-
point scale from 0 to 3 in terms of its occurrence and its
intensity during the last seven days. The cut-off for clin-
ically relevant depressive symptoms is 20. Cronbach’s
Alpha for the BDI-2 was .92.
Higher scores in these three instruments indicate
greater psychopathology.
The treating therapist rated the patient’s motivation
for changing their eating disorder behaviours at ad-
mission on a scale from 0 (not at all motivated) to 4
(highly motivated).
Additionally, sociodemographic and clinical character-
istics (e.g. BMI ad admission and at discharge, duration
of inpatient treatment, duration of the eating disorder,
comorbidity) were available from each patient’s clinical
records.
Statistical analysis
In order to examine the effectiveness of inpatient treat-
ment for anorexia nervosa, results were analysed in
three different ways:
 Statistical group comparisons (repeated measures
analyses of variance (rANOVAs) with treatment
duration as covariate).
 Calculation of effect sizes.
 Assessment of treatment outcome on the basis of
individual changes according to the criteria of
clinical significance [14].
Effect sizes were calculated using the formula (Mpre-
Mpost)/SDpre. Interpretation of the effect size was cor-
rected by the effects of an untreated control group, i.e.
ES = 0.10, as proposed for single group pre-post study
designs by Grawe et al. [29]. Therefore, an ES > 0.30 is
considered a small effect, an ES > 0.60 a medium effect
and an ES > 0.90 a large effect.
The concept of clinical significance
The concept of clinical significance by Jacobson and col-
leagues [14,20] is a construct used to evaluate clinically
meaningful changes resulting from therapy. It consists of
a two-part criterion: To qualify as clinically significantly
improved after treatment, a patient has to i) show a reli-
able change, i.e. statistically significant improvement and
ii) cross the cut-off point for a clinically significant change.
The criterion of statistical significance/reliable change
To classify a patient as having shown a statistically sig-
nificant change (i.e. that the observed change is notbased on errors of measurement or chance), an individ-
ual minimal pre-post change (from admission to dis-
charge) is necessary.
Therefore, the reliable-change-index (RCI) has to be ex-
ceeded, and this is calculated as follows: RCI ¼ Xpre−XpostSdiff >









Here Xpre represents the pre-test score and Xpost the
post-test score of a patient. Additionally, the standard
error of measurement (SE), the standard deviation of the
patient group at pretest (s1) and a measure for the reli-
ability of the measurement (rxx = Cronbach’s α) are in-
cluded in this formula. Sdiff stands for the standard error
of difference between the two test scores.The criterion of clinical significance
A reliable change is considered to be a precondition for
a clinically relevant change. As a second step, a cut-off is
defined in order to assess whether a patient should be
assigned to the healthy or clinical group after treatment.
For the present study, cut-off point C according to
the classification by Jacobson and Truax [14] was
used. This cut-off is a weighted midpoint between the
means of a functional and a dysfunctional population
[30]: C ¼ SD0M1þSD1M0SD0þSD1 . M0 and SD0 represent the mean
and standard deviation of the normative sample, M1 and
SD1 the mean and standard deviation of the patient group
at pre-test. Norms for the healthy samples were taken
from the applicable manuals [24,26,28]. Reaching the cut-
off means that, following treatment, a patient is closer to
the mean of a functional population than to the mean of
inpatients with anorexia nervosa at admission.
According to the cut-off, patients can be classified into
five treatment outcome groups:
1. Normative: patients with normative scores both at
admission and discharge.
2. Deteriorated: statistically significant worsening
(RCI ≤ −1.96) of patients; clinical significance is not
of interest as the result is clearly unwanted.
3. Unchanged: patients with scores above norm at
admission and statistically non-significant individual
changes at discharge.
4. Reliably improved: statistically significant
improvement (RCI ≥ 1.96) of patients between
pre- and post-measurement.
5. Clinically significantly improved: patients with
statistically significant improvement and symptoms
within the normal range of a functional sample at
the end of therapy.
In this study, only patients from groups 2 through 5
were considered in the analyses of each separate scale.
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improvement was not an issue.
To investigate differences between the different treat-
ment outcome groups, ANOVAs or Chi-Square-Tests
with post-hoc tests were calculated.
A stepwise binary logistic regression was calculated
using the backward likelihood ratio method to identify
predictors of clinically significant changes in the EDI-2
Global score. We divided patients into two groups: those
who showed clinically significant change and those who
did not (i.e. we grouped together patients who showed
reliable change, patients who were unchanged, and
patients who had deteriorated). We first tested for differ-
ences between these two groups in terms of sociodemo-
graphic variables, clinical characteristics and baseline
subscales. In a second step, we included these variables
as predictors in the regression analyses, if they showed
significant differences between the patient groups and if
they showed no multi-collinearity.
All statistical analyses were performed with SPSS ver-
sion 22.0. The Bonferroni correction was used for
multiple-comparison correction. Based on running 15 F-
tests alpha was set at .003. To reflect actual clinical prac-
tice, patients who were discharged regularly, as well asFigure 1 Flow chart of patient sample. Notes: BMI = Body-mass-index, E
BDI-2 = Beck depression inventory-2.those who were discharged prematurely, were included
in analyses, with no replacement of missing values.
Results
Study sample
As shown in the participant flow chart (Figure 1) be-
tween January 2009 and January 2014 748 adult female
patients with anorexia nervosa (F50.00/F50.01) were
treated as inpatients in the Schoen Klinik Roseneck. Due
to administrative regulations, EDI-2 data were not avail-
able from n = 313 patients. There were no significant dif-
ferences between those for whom EDI-2 data were
available and those for whom data were unavailable in
terms of BMI at admission, age, treatment duration, dur-
ation of illness, previous inpatient and outpatient treat-
ments. Furthermore, there were no differences in BMI
change during inpatient treatment between these two
groups. A total of 435 inpatients with anorexia nervosa
were included in the analyses of whom n = 294 regularly
completed treatment and n = 141 were premature dis-
charges (see Table 1 for more detail). Patients had a
mean age of M = 26.36 (SD = 9.02). BMI at admission
was 14.56 kg/m2 (SD = 1.74). Individual length of admis-
sion varied considerably (6–260 days) and mean durationDI-2 = Eating disorder inventory-2, BSI = Brief symptom inventory,
Table 1 Sociodemographic and clinical characteristics of
anorexia nervosa inpatients (N = 435) at admission
Variables M (SD) Range
Age (years) 26.36 (9.02) 18 - 70
Inpatient treatment duration (days) 91.79 (44.26) 6 - 260
Body-Mass-Index (kg/m2) 14.56 (1.74) 9.69 - 17.48
Duration of the eating disorder (years) 8.84 (7.81) 1 - 50
Number of previous inpatient treatment 1.86 (2.45) 0 - 15









Insufficent insurance coverage 1 (0.2)
Transfer 12 (2.8)
Subtype of anorexia nervosa
F 50.00 (Restricting Type) 316 (72.6)
F 50.01 (Binge Eating/Purging Type) 111 (25.5)
Comorbidity1
Moderate depressive episode (F32.1) 117 (26.9)




Recurrent severe depressive disorder2 (F33.2) 42 (9.7)
Social phobia (F40.1) 39 (9.0)
Predominantly compulsive acts (F42.1) 24 (5.5)




Notes: 1Only diagnoses pertaining to more than 5% of included patients are
indicated, 2without psychotic symptoms.
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sociodemographic and clinical characteristics of the sam-
ple are presented in Table 1. For participants who were
discharged prematurely, there were no differences in
sociodemographic and clinical variables between those
with available EDI-2 discharge data and those without.
However, differences emerged for the patients who were
discharged regularly: those with no discharge data had a
lower BMI at admission, more depressive symptoms, more
general psychopathology, and more previous inpatient
treatments than those with discharge data.
Body weight and eating disorder symptomatology
BMI rose on average from 14.56 kg/m2 (SD = 1.74) to
17.18 kg/m2 (SD = 1.86) (ES = 1.51) during inpatient
treatment. Treatment duration significantly contributedto pre-post change in body weight. The total mean
weight increase was 7.33 kg (SD = 4.31). The mean
weight increase per week was 0.84 kg (SD = 0.56). 52.2%
of the patients remained in the anorectic BMI range (≤
17.5) at discharge. Of 435 patients 108 (24.8%) reached a
BMI ≥ 18.5 at discharge. For patients who were dis-
charged regularly, percentages were 38.3% (BMI ≤ 17.5)
and 33.1% (BMI ≥ 18.5).
As shown in Table 2, all scales of the EDI-2 indicated
statistically significant changes after treatment. The lar-
gest effect sizes were found for Drive for Thinness, the
EDI-2 Global score and Interoceptive Awareness, whereas
the lowest were achieved for Body Dissatisfaction, Inter-
personal Distrust and Perfectionism. Treatment duration
only had a significant effect on pre-post change in In-
teroceptive Awareness.
Additional file 1 shows mean and standard deviations of
community norms, the patients’ pre-treatment scores and
the reliabilities used to calculate cut-offs for a clinically
significant change. Furthermore, numbers of patients in
the normative range for each scale are given in Additional
file 1.
Results show that 27.7% of the patients improved reli-
ably on the Global score of the EDI-2. 35.6% fulfilled the
criteria for a clinically significant change. In contrast,
34.5% remained unchanged and 2.2% showed worsened
symptoms (see Figure 2). Additional file 2 presents the
classification of treatment outcome based on the criteria
of Jacobson and Truax [14] for all subscales of the EDI-2.
General psychopathology
Change on the GSI of the BSI was statistically significant.
Treatment duration had a significant effect on pre-post
change in regard to GSI. The effect size was medium (ES =
0.82) (see Table 2). 32.0% of the patients showed reliable
changes during inpatient treatment according to the GSI,
34.1% were clinically significantly improved, 30.8% un-
changed and 3.0% worse (see Figure 2).
Depression
Depressive symptoms significantly improved after treat-
ment with a large effect size of ES = 1.26 (see Table 2). Re-
garding the BDI-2, the distribution of treatment outcome
groups was as follows: 20.0% of patients were reliably im-
proved, 55.3% were clinically significantly improved and
23.0% remained unchanged. 1.7% of the patients deterio-
rated (see Figure 2).
Differences between deteriorated/unchanged, reliably
improved and clinically significantly improved patients in
regard to baseline variables
Since the number of deteriorated patients was very low,
these were combined with the unchanged patients. Table 3
shows that clinically significantly improved patients had
Table 2 Pre-post results regarding BMI, EDI-2, BSI and BDI-2
Pretreatment Posttreatment rANOVAs ES
M (SD) M (SD)
Pre-post change Interaction between treatment
duration and pre-post change
F (df) p F (df) p
BMI 14.56 (1.74) 17.18 (1.86) 24.77 (1) <.001 256.04 (1) <.001 1.51
EDI-2
Drive for Thinness 29.38 (8.80) 21.69 (8.69) 47.96 (1) <.001 3.15 (1) .077 0.87
Bulimia 16.95 (9.38) 10.62 (5.03) 25.50 (1) <.001 1.97 (1) .162 0.67
Body dissatisfaction 38.24 (9.39) 33.85 (10.49) 24.53 (1) <.001 0.44 (1) .510 0.47
Ineffectiveness 36.93 (10.38) 30.10 (10.60) 34.03 (1) <.001 1.57 (1) .211 0.66
Perfectionism 22.90 (6.20) 20.97 (5.98) 8.09 (1) .005 0.48 (1) .487 0.31
Interpersonal distrust 23.77 (6.69) 21.11 (6.65) 9.18 (1) .003 2.89 (1) .090 0.40
Interoceptive awareness 35.91 (9.52) 28.90 (9.42) 24.33 (1) <.001 5.50 (1) .020 0.74
Maturity fears 27.72 (7.90) 24.03 (7.43) 9.72 (1) .002 3.33 (1) .069 0.47
Asceticism 25.97 (7.49) 21.84 (7.26) 14.75 (1) <.001 2.33 (1) .128 0.55
Impulse regulation 28.36 (7.62) 24.29 (7.89) 19.62 (1) <.001 0.63 (1) .428 0.53
Social insecurity 28.27 (6.63) 24.84 (7.10) 19.37 (1) <.001 0.85 (1) .356 0.52
EDI-2 Global score 313.69 (62.85) 262.00 (66.42) 42.95 (1) <.001 3.79 (1) .052 0.82
BSI GSI 1.33 (0.70) 0.76 (0.57) 32.19 (1) <.001 11.17 (1) .001 0.82
BDI-2 28.53 (11.60) 13.97 (11.24) 52.49 (1) <.001 3.06 (1) .082 1.26
Notes: BMI = Body-mass-index, EDI-2 = Eating disorder inventory-2, BSI = Brief symptom inventory, GSI = Global severity index, BDI-2 = Beck depression inventory-2,
ES = effect size, treatment duration as covariate.
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chopathology at admission, and a lower rate of comorbid
recurrent severe depression and of posttraumatic stress
disorder. They were more motivated for treatment and
had a higher rate of moderate depression. Deteriorated/
unchanged patients showed a higher rate of comorbid




















Figure 2 Treatment outcome on the Global scores using the criteria o
BSI = Brief symptom inventory, BDI-2 = Beck depression inventory-2.Predictors for a clinically significant change in the Global
score of the EDI-2
A higher motivation for change as well as more depressive
symptoms turned out to be significant predictors for a
clinically significant change whereas body dissatisfaction,
impulse regulation, social insecurity and education were
negative predictors (see Table 4). These factors explained










f clinical significance. Notes: EDI-2 = Eating disorder inventory-2,







M (SD) M (SD) M (SD) ANOVA Post-hoc
Age (years) 25.35 (8.87) 25.94 (8.40) 26.19 (7.79) F (2, 168) = 0.16, p = .853 G1 = G2 = G3
Inpatient treatment duration (days) 88.56 (42.01) 103.41 (37.82) 86.37 (34.78) F (2, 168) = 3.03, p = .051 G3 = G1 = G2
Body-Mass-Index (kg/m2) at admission 14.65 (1.54) 14.75 (1.80) 14.95 (2.02) F (2, 168) = 0.44, p = .645 G1 = G2 = G3
Duration of the eating disorder (years) 8.27 (6.77) 8.65 (8.09) 8.50 (6.78) F (2, 168) = 0.04, p = .958 G1 = G3 = G2
Number of previous inpatient treatment 1.96 (1.64) 1.75 (1.47) 1.73 (1.33) F (2, 168) = 0.43, p = .649 G3 = G2 = G1
Number of previous outpatient treatment 2.32 (2.88) 2.10 (2.34) 1.29 (1.54) F (2, 168) = 2.96, p = .055 G3 = G2 = G3
Motivation 2.09 (1.11) 2.43 (1.17) 2.54 (1.07) F (2, 213) = 3.45, p = .034 G2 = G1 < G3
BDI-2 at baseline 30.34 (10.83) 37.51 (9.11) 27.21 (10.07) F (2, 168) = 14.13, p < .001 G3 = G1 < G2
BSI at baseline 1.56 (0.66) 1.87 (0.51) 1.24 (0.59) F (2, 168) = 14.01, p < .001 G3 < G1 < G2
EDI-2 Global score at baseline 333.59 (46.52) 373.10 (32.55) 305.77 (33.60) F (2, 168) = 38.78, p < .001 G3 < G1 < G2
n (%) n (%) n (%) χ2-Test Post-hoc
Comorbidity





12 (11.8) 15 (19.5) 4 (4.0) χ2 (2, 278) = 10.48, p = .005 G3 < G2 = G1
G3 = G2




Still in school 4 (3.9) 3 (3.9) 9 (9.1) H(2) = 7.34, p = .026 G3 = G1
G1 = G2No graduation 1 (1.0) - -
Secondary general school certificate 7 (6.9) 4 (5.2) 7 (7.1) G3 < G2
Intermediate school certificate 25 (24.5) 13 (16.9) 30 (30.3)
Higher education entrance qualification 64 (62.7) 56 (72.7) 53 (53.5)
Notes: G1 = Group 1, G2 = Group 2, G3 = Group 3, 1without psychotic symptoms. Only comorbidities with significant differences are presented.
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The aim of this study was to evaluate the effectiveness
of inpatient treatment for anorexia nervosa according to
the criteria of clinical significance of Jacobson and col-
leagues [14,20]. This construct allowed detailed analysesTable 4 Predictors of a clinically significant change of
EDI-2 global score
ß S.E. Wald p OR (95% CI)
EDI-2 Body dissatisfaction -.070 .02 9.38 .002 0.93 (0.89-0.98)
EDI-2 Impulse regulation -.066 .03 4.26 .039 0.94 (0.88-1.00)
EDI-2 Social insecurity -.088 .04 5.23 .022 0.92 (0.85-0.99)
Moderate depressive
episode (F32.1)
1.049 .39 7.21 .007 2.85 (1.33-6.13)
Education -.475 .20 5.69 .017 0.62 (0.42-0.92)
Motivation for change .401 .18 5.19 .023 1.49 (1.06-2.11)
Note: EDI-2 = Eating disorder inventory-2.of treatment outcome on an individual basis. The results
showed that – depending on the outcome measure –
one-third to more than one half of the patients showed
clinically significant changes. Furthermore, the rate of
patients with reliable changes was more than 30%.
Lambert and Ogles [31] assume that 25-30% of pa-
tients generally do not change during psychotherapy and
that about 5-10% even worsen during treatment. Our
non-response rates are somewhat higher than the ones
reported by these authors, while deterioration rates are
somewhat lower.
Our rate of clinically significant improvement following
inpatient treatment for anorexia nervosa is comparable to
the findings of Calugi and colleagues [21], whereas the
non-response rate found in our sample was only half of
that in the comparison study. In contrast to our study,
which used the self-rated EDI-2 Global score to evaluate
treatment outcome, Calugi and colleagues [21] used the
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instrument might have overestimated effects compared to
the expert rating.
The high effect size of ES = 1.51 for the BMI is larger
than a meta-analytically calculated effect size of inpatient
treatment for anorexia nervosa with ES = 1.19 (CI: 1.07 -
1.30) [32]. However, despite the considerable weight gain,
52.2% of patients remained in the anorectic BMI range at
discharge. This result is comparable with Goddard and
colleagues [19] who also found that more than half of their
patients did not reach a BMI > 17.5 during inpatient treat-
ment. One explanation is the severity of anorexia nervosa
in inpatient samples. In our sample individuals suffered
from long-term anorexia nervosa (mean illness duration of
almost 10 years) and had a rather low BMI at admission.
For depression, as measured by the BDI-2, the large ef-
fect size is consistent with the finding by Bowers et al.
[10]. The medium effect sizes found for the Global
scores of EDI-2 and the general psychopathology in this
study are in line with effects shown in previous studies
examining the effectiveness of inpatient treatment for
anorexia nervosa [12,13,33,34].
Treatment duration had a significant effect on BMI
change as well as on changes in Interoceptive Awareness
and general psychopathology (GSI). Other subscales were
not significantly influenced by treatment duration. This is
in line with results from Morris et al. [11], who found that
length of inpatient stay was significantly correlated with
BMI change but not with change in EDE questionnaire.
Collin et al. [12] also reported that length of current ad-
mission was a predictor of BMI change, but not of EDE
change or change in the SCL-90 (Symptom Checklist-90)
global severity index [35].
When comparing deteriorated/unchanged, reliably im-
proved and clinically significantly improved patients, dif-
ferences in regard to numerous baseline variables were
found. Clinically significantly improved patients were less
severely ill at admission, i.e. they showed less symptoms in
terms of general and eating disorder psychopathology at
admission and had a lower rate of comorbid disorders (re-
current severe depression, posttraumatic stress disorder).
One plausible explanation as to why these patients had
the highest rate of clinically significant changes is that
lower scores at baseline make it easier to reach the cut-off
for a clinically significant change. Clinically significantly
improved patients were also more motivated, which may
also explain why they showed the most pronounced treat-
ment effects. Comorbid depression was also observed in
patients with clinically significant changes. A positive pro-
tective effect of depression was also found by Zeeck et al.
[36], who reported that inpatients with anorexia nervosa
and comorbid depression stayed longer in psychotherapy
than those without comorbid depression. These patients
therefore have a higher chance for clinically significantchanges. Deteriorated/unchanged patients showed a higher
rate of severe comorbid conditions (recurrent severe de-
pression, posttraumatic stress disorder).
The regression analysis emphasized the relevance of
high internal motivation for change as a predictive factor
for a better treatment outcome at the time of discharge.
Previous studies have also found that a higher baseline
motivation is an important predictor for change in an-
orexia nervosa inpatients [37,38]. These results suggest
that motivational strategies should be a key starting
point for improving the effectiveness of inpatient treat-
ment for anorexia nervosa. One possible future approach
is to increase the patients’ readiness for change, for ex-
ample using Motivational Interviewing techniques [39]
which also showed promise for the treatment of patients
with eating disorders [40]. Furthermore, body dissatisfac-
tion was identified as a negative predictor of a clinically
significant change. This is in line with results from other
studies which have found that body dissatisfaction is a
negative predictor of weight increase [41,42]. In our
study, impulse regulation was a negative predictor of
short-term outcome. Fichter et al. [43] also found that
impulse regulation was a negative predictor at 12 year
follow-up. While Karllson et al. [41] found that social inse-
curity was a positive predictor for weight gain, we found
that it was a negative predictor for clinically significant
change. It may be that social insecurity leads to reduced
therapeutic alliance and therefore a less favourable treat-
ment outcome. A comorbid moderate depressive episode
was found to be a positive predictor of clinically significant
change. This contrasts with previous studies which have
shown that depressive symptoms are a negative predictor
of treatment outcome [43]. Furthermore, Calugi et al. [44]
showed that there were no differences in outcome be-
tween eating disorder patients with or without a comorbid
major depressive disorder. Our results should be inter-
preted carefully since comorbidity was not assessed by a
structured clinical interview such as the Structured Clinical
Interview for DSM Disorders [45], but rather based on ex-
pert opinion. When comparing values of depressive symp-
toms among the unchanged, the reliably improved and
clinically significantly improved patients in our study, re-
sults showed that clinically significantly improved patients
had the lowest depressive symptoms. Finally, a higher edu-
cation was identified as negative predictor for treatment
outcome. This contrasts with findings from Huas et al.
[46], who found that low educational status was a predictor
of dropout from inpatient treatment for anorexia nervosa,
which is linked in general to poorer outcomes.
Strengths and limitations
To the best of our knowledge, this study includes the
largest sample size of anorexia nervosa patients treated
as inpatients. Furthermore, strength of the study is that
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ables a more realistic view of treatment outcomes than
comparisons of means and effect sizes do [47]. A further
advantage of the study is the naturalistic sample. In
comparison to data from randomised controlled trials,
data from naturalistic settings may yield more clinically
useful findings [48] because they represent the heteroge-
neous nature of the cases, settings, referral routes, and
therapists that characterise everyday clinical practice
[49]. These factors enable more valid conclusions to be
drawn about treatment improvement.
The strength of the clinical significance concept lies in
its applicability to individual cases. Furthermore, evalu-
ation of each individual patient with regard to normative
functioning is of great value for clinical practice [30].
There are several limitations. First, the data do not
represent all patients with anorexia nervosa admitted in
the defined period but rather those for whom baseline
and discharge questionnaires were available (about 50%).
There were no differences between those with and with-
out missing baseline data in terms of sociodemographic
and clinical variables. Furthermore, there were no differ-
ences in BMI change during inpatient treatment. How-
ever, there were differences between those with and
without discharge questionnaires. Since patients who did
not complete discharge assessment were more severely
ill, results may have overestimated treatment effects. On
the other hand, we included outcome data from patients
who were prematurely discharged so that our results
may after all give a conservative evaluation of treatment
outcome. Analyses of only those patients who were dis-
charged regularly might have revealed more positive out-
comes. Second, all data except those for the BMI, were
based on self-ratings, and no structured clinical inter-
view was conducted. Diagnoses were finally fixed at the
end of treatment, giving the expert rater a broad vision
of the patient’s behaviour. Third, no follow-up data
could be collected to provide data on the long-term out-
come of inpatient treatment for anorexia nervosa.
Fourth, although one item rated therapy motivation as a
predictor of treatment outcome, this has neither been
validated against other measures that assess motivation,
nor has its reliability been established. One study asses-
sing readiness to change (University of Rhode Island
Change Assessment, [50]) in inpatients with anorexia
nervosa found that BMI change was not predicted by
the stage of change of the patients [51]. A further limita-
tion of the patient’s motivation being rated by the ther-
apist is that the rating data may reflect the motivation of
the therapist to some extent, and may influence the mo-
tivation of the therapist and consequently treatment
quality. Fifth, the method of clinical significance has
weaknesses. A statistical limitation of this approach is
regression to the mean. Patients with higher scores atadmission are those most likely to make huge improve-
ments [52]. Also cut-off point C as a cut-off point be-
tween normal and dysfunctional distribution can vary
considerably among studies as this criterion depends on
the symptom severity in the study sample at baseline.
Furthermore, the use of the two criteria to evaluate clin-
ically significant change represents a more stringent
measure than most of the previously used criteria. More-
over, one needs to take into account that treatment is, in
most cases, not completed when inpatient care con-
cludes. In most cases, inpatient psychotherapy repre-
sents a specific phase of a long-term treatment process.
Consequently, additional outpatient therapy is required
to ensure further improvements of symptoms and a
long-term stabilization of achieved effects. There is one
caveat, however: patients with anorexia nervosa are often
chronically ill and becoming completely symptom-free
might be unrealistic, even in the long run.
The paradigm of ‘clinically relevant treatment effects’ is
worthy of some discussion in general. Self-ratings that
focus on the assessment of symptoms are certainly import-
ant in this context, but it is still only one aspect that must
be complemented by other perspectives (e.g. expert rat-
ings). Other factors may equally well indicate clinically rele-
vant treatment effects (e.g. acceptance of disease, improved
quality of life, increased knowledge and capability to deal
with one’s own illness, provision of a basis for improve-
ment of symptoms in the ensuing outpatient therapy).
Although inpatient treatment for anorexia nervosa is ef-
fective, a certain percentage of patients do not benefit from
it – at least in certain symptom areas. There are several
reasons for the absence of significant or clinically relevant
treatment effects. For example, a lack of motivation may
reduce response to treatment. Additionally, a lack in quality
of the therapy (e.g. a poor therapeutic relationship, over-
estimation of the patient’s capabilities) may contribute to
non-response. Moreover, adverse external events that occur
during inpatient treatment such as relationship breakups,
job loss, emerging conflicts, may result in non-response or
even a deterioration of symptoms in some patients.
Finally, there is the question of how the concept of
clinical significance can be integrated in other definitions
of treatment outcome. In outcome research there are
many different terms used to describe treatment out-
come, e.g. response, (partial) remission, recovery and re-
lapse that are often differently defined [53]. In eating
disorders research there are also a variety of definitions
of outcome success that are used [54-57]. Couturier
et al. [54] reviewed various conceptualizations of remis-
sion in adolescent anorexia nervosa and reached the con-
clusion that remission is best defined as the attainment of
a certain weight and/or the attainment of normal EDE
scores (within 1 or 2 SD of the normal range, depending
on the distribution). Bardone-Cone et al. [57] defined
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orexia nervosa, showing a BMI ≥ 18.5, no binging or pur-
ging, and EDE scores within 1 SD of community norm for
each subscale. All these definitions compare individuals’
outcomes with a norm at a predefined assessment time.
However, they do not consider changes resulting from
treatment. As Frank et al. [53] stated, remission and recov-
ery are an assessment of outcome at a single point and are
not entirely dependent on treatment. However, response is
a change due to treatment that requires baseline and post-
treatment scores. In this sense, the first criterion of the
concept of clinical significance (reliable change) assesses
response to treatment. A clinically significant change re-
quires both response to treatment as well as achieving a
functional range at endpoint assessment. A clinical signifi-
cant change may therefore be seen as remission, but con-
siders response to treatment, too. Therefore, the criteria of
clinical significance may be a more appropriate definition
for evaluating treatment outcome.
Future research
In order to optimize treatment, future studies should ex-
plore the complex interplay of factors that may prevent
patients with anorexia nervosa from non-responding to
inpatient treatment. Then, treatment strategies for those
should be developed. For those who improved during in-
patient treatment, the challenge remains in maintaining
therapy success following discharge. More attention
should be paid to relapse prevention strategies, of which
technology-based relapse prevention may be particularly
useful [58,59]. Additional research should also address
clarifying the impact of depressive symptoms or of de-
pressive comorbidity on outcome for anorexia nervosa
patients. Furthermore, future research should also inves-
tigate if patients’ therapy motivation or stage of change
as assessed by validated disorder-specific measures [60-62]
are a predictor for a clinically significant change.
Conclusions
Inpatient treatment of anorexia nervosa is highly effect-
ive in restoring weight. A good proportion of patients
show reliable changes in terms of eating disorder psy-
chopathology, general psychopathology and depression.
However, a significant proportion of non-responders re-
main. Supplementing group statistics with analyses of
outcome on an individual level is suitable for obtaining a
more precise picture of treatment outcome and is of im-
mense practical relevance.
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